GANX logo

GANX
Gain Therapeutics Inc

2,605
Mkt Cap
$76.04M
Volume
411,051.00
52W High
$4.34
52W Low
$1.41
PE Ratio
-2.93
GANX Fundamentals
Price
$1.80
Prev Close
$1.84
Open
$1.83
50D MA
$2.11
Beta
1.18
Avg. Volume
815,696.78
EPS (Annual)
-$0.6115
P/B
4.08
Rev/Employee
$0.00
$86.05
Loading...
Loading...
News
all
press releases
HC Wainwright Has Positive Estimate for GANX Q1 Earnings
Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for Gain Therapeutics in a research note issued on Monday, March 30th. HC Wainwright...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results
Gain Therapeutics (NASDAQ:GANX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03...
MarketBeat·16d ago
News Placeholder
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside...
MarketBeat·18d ago
News Placeholder
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday
Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...
MarketBeat·24d ago
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...
MarketBeat·26d ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...
MarketBeat·2mo ago
News Placeholder
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·3mo ago
News Placeholder
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop
Gain Therapeutics (NASDAQ:GANX) highlighted early clinical and biomarker findings from the first 90 days of its ongoing Phase 1b open-label study evaluating GT-02287 in people with Parkinson's...
MarketBeat·3mo ago
<
1
2
...
>

Latest GANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.